Mark Strobeck - 20 May 2025 Form 4/A - Amendment Insider Report for ROCKWELL MEDICAL, INC. (RMTI)

Reporting relationship: President and CEO, Director
Issuer ticker: RMTI
Reported as of: 20 May 2025
Net transaction value: $0
SEC form: 4/A - Amendment
Accepted by SEC: 17 Apr 2026, 18:49:01 UTC
Original report date: 21 May 2025
Prior SEC filing: 02 Apr 2025
Next SEC filing: 03 Jul 2025
Source filing: View source filing
Reporting owner signature: /s/ Megan Timmins, Attorney-in-Fact for Mark Strobeck

Key filing fact

Mark Strobeck filed Form 4/A - Amendment for ROCKWELL MEDICAL, INC. (RMTI) on 17 Apr 2026.

Key facts

This page summarizes Mark Strobeck's Form 4/A - Amendment filing for ROCKWELL MEDICAL, INC. (RMTI).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 17 Apr 2026, 18:49.

Change

Previous filing in this sequence was filed on 02 Apr 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reporting Owners (1)

CIK 0001599219 Primary reporting owner

Strobeck Mark

Relationship: President and CEO, Director
Address: C/O ROCKWELL MEDICAL, INC., 30142 WIXOM ROAD, WIXOM
Signature: /s/ Megan Timmins, Attorney-in-Fact for Mark Strobeck
Signature date: 17 Apr 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RMTI transaction Derivative

Performance-based restricted stock units

Award

Transaction value
Shares: +352,000
Change %
Price: $0.000000^*
Shares after: 352,000
Date: 20 May 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 352,000
Exercise price
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

These are performance-based restricted stock units ("PSU") with terms as follows. The term of each PSU award runs from the grant date through the third anniversary of the grant date. Any unvested PSUs remaining after the third anniversary will be cancelled. The performance period for the award is the same three-year period. PSUs will vest on or after the first anniversary of the grant date only if the stock price meets the performance hurdle. The performance hurdle is met if the average closing price of the Company's common stock over any 60 consecutive trading days during the performance period equals two times the base price. The base price was calculated as the average closing price over the ten trading days ending on the trading day prior to the grant date and is $2.14 for this award.

SEC remarks

This award was inadvertently omitted from the original Form 4.